<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02975310</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-0801</org_study_id>
    <nct_id>NCT02975310</nct_id>
  </id_info>
  <brief_title>In-clinic Endoscopic Polypectomy for Chronic Sinusitis With Nasal Polyps</brief_title>
  <official_title>Endoscopic Polypectomy Performed In Clinic for Chronic Rhinosinusitis With Polyps: The EPIC Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic rhinosinusitis, also called chronic sinusitis, is a very common life-long disease&#xD;
      affecting over 5% of the Canadian population. Its symptoms, including daily facial pain and&#xD;
      headache, an inability to breath through the nose and complete smell loss, regularly impair&#xD;
      one's ability to work and to enjoy and participate in daily activities. The annual cost of&#xD;
      chronic sinusitis to Canada is estimated at $1.3 billion while the government pays an&#xD;
      estimated $860 million yearly for chronic sinusitis treatment. Chronic sinusitis with polyps,&#xD;
      the most common type of chronic sinusitis, is usually treated with a combination of&#xD;
      medications and surgery. Until now, surgical treatment has only been performed in the&#xD;
      operating room, at a cost of about $3500 per procedure. But, recent studies have shown that a&#xD;
      new procedure, &quot;in-clinic polyp removal&quot;, can provide an improvement in patient symptoms to&#xD;
      levels equal to those for sinus surgery performed in a hospital operating room. Moreover, in&#xD;
      clinic polyp removal has additional advantages including a shorter procedure recovery time, a&#xD;
      significantly lower cost to the health care system (about one-tenth the cost or $450), and a&#xD;
      shorter wait time for treatment. With the proposed pragmatic trial, the investigators will&#xD;
      determine whether the in clinic polyp removal procedure is as good as sinus surgery in the&#xD;
      operating room at controlling patient symptoms of chronic sinusitis. The investigators will&#xD;
      also determine the cost and health-benefits for a patient, the healthcare system and for&#xD;
      society of in clinic polyp removal in comparison to sinus surgery done in a hospital&#xD;
      operating room. The investigators will then know if this new treatment, in clinic polyp&#xD;
      removal, can replace sinus surgery as the standard of care for these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic rhinosinusitis (CRS) is common, with a Canadian prevalence of 5%, and associated with&#xD;
      significant morbidity having a health state utility value equivalent to end-stage renal&#xD;
      disease. Understandably, CRS impairs workplace productivity but that productivity&#xD;
      substantially increases following surgical treatment.&#xD;
&#xD;
      However, the wait time to receive surgical treatment (ESS) maybe up to 8 months or longer,&#xD;
      with a cost to the Government of $3500/ESS procedure. The annual direct cost of CRS is&#xD;
      estimated at $860 million with an overall financial impact of 1.3 billion dollars per year&#xD;
      for Canada. Endoscopic polypectomy in clinic (EPIC), a potential disruptive innovation, is a&#xD;
      drastically deescalated form of ESS performed in clinic instead of the operating room. EPIC&#xD;
      appears to provide quality of life (QofL) improvement equivalent to that reported for ESS.&#xD;
      EPIC has a shorter wait time and lower cost to a government, i.e. nearly one-tenth of ESS or&#xD;
      about $450. A pilot economic evaluation study demonstrated that EPIC was cost-effective&#xD;
      compared to ESS. This has created a controversy about which treatment should be employed for&#xD;
      these patients. Further, a recent Cochrane review identified the need for high-quality&#xD;
      randomised controlled trials to determine if ESS has additional benefit over polypectomy as&#xD;
      there is currently insufficient evidence to draw conclusions about the superiority of&#xD;
      polypectomy or ESS for the management of CRS with polyps.&#xD;
&#xD;
      The proposed national multicenter randomised controlled trial will determine whether EPIC is&#xD;
      non-inferior to the current treatment standard, ESS, in QofL improvement for patients with&#xD;
      CRS with polyps. It will also assess the cost-effectiveness of performing EPIC in place of&#xD;
      ESS. The investigators hypothesize that EPIC will be non-inferior to ESS for QofL improvement&#xD;
      while reducing health care cost. This would imply that EPIC is a dominant strategy and that&#xD;
      the ESS strategy represents over-treatment in this patient population. The study findings&#xD;
      would position EPIC into the current CRS treatment paradigm thereby transforming care and&#xD;
      reducing costs both nationally and internationally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2017</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sinonasal Outcome Test-22 (SNOT-22)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Nasal Inspiratory Flow (PNIF):</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iowa Satisfaction with Anesthesia Scale (ISAS)</measure>
    <time_frame>3 months</time_frame>
    <description>Patient satisfaction with anesthesia for the treatment procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP)</measure>
    <time_frame>3 months</time_frame>
    <description>Work Impairment related to chronic rhinosinusitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>3 months</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Health Resource Consumption Survey</measure>
    <time_frame>3 months</time_frame>
    <description>Individual Health Resource Consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Lund-Kennedy Endoscopic Scoring Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Endoscopic inflammation of the nose and paranasal sinuses after treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual Analogue Scale (VAS) for satisfaction with assigned procedure</measure>
    <time_frame>3 months</time_frame>
    <description>Satisfaction with assigned procedure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Sinusitis</condition>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Endoscopic polypectomy in clinic (EPIC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endoscopic Sinus Surgery (ESS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic polypectomy in clinic (EPIC)</intervention_name>
    <description>The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.</description>
    <arm_group_label>Endoscopic polypectomy in clinic (EPIC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic Sinus Surgery (ESS)</intervention_name>
    <description>The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.</description>
    <arm_group_label>Endoscopic Sinus Surgery (ESS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>General Anesthesia</intervention_name>
    <description>ESS will be performed under general anesthesia in the operating room</description>
    <arm_group_label>Endoscopic Sinus Surgery (ESS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Local and topical anesthesia</intervention_name>
    <description>EPIC will be performed under topical and local anesthesia in a clinic setting</description>
    <arm_group_label>Endoscopic polypectomy in clinic (EPIC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Diagnosis of chronic rhinosinusitis with polyps requiring surgical treatment after&#xD;
             having been treated with medical therapy as designated by the Canadian clinical&#xD;
             practice guidelines for acute and chronic sinusitis. 15&#xD;
&#xD;
          3. Bilateral nasal polyps present of Grade ≥ 2 on each side as determined by the&#xD;
             Lildholdt scale score measured by nasal endoscopy at the screening visit.&#xD;
&#xD;
          4. Must have nasal blockage score greater than or equal to 2 on the sinonasal outcome&#xD;
             test SNOT-22 at the screening visit.&#xD;
&#xD;
          5. Must have an American Society of Anesthesiologists physical status PS3 classification&#xD;
             or less.&#xD;
&#xD;
          6. Participants with comorbid asthma or chronic obstructive pulmonary disease (COPD) must&#xD;
             have stable disease with no exacerbations (no emergency room visits, hospitalisations,&#xD;
             or oral or parental steroid use for these lower respiratory conditions) within 3&#xD;
             months before the screening visit.&#xD;
&#xD;
          7. Must be capable, in the opinion of the investigator, of providing informed consent to&#xD;
             participate in the study. Participants must sign an informed consent document&#xD;
             indicating that they understand the purpose of and procedures of the study and are&#xD;
             willing to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or breast feeding as per patient's report&#xD;
&#xD;
          2. Patients with hyperplastic polyps or polyps large enough that they result in external&#xD;
             nasal deformity&#xD;
&#xD;
          3. Facial pain/pressure score higher than 2 on the sinonasal outcome test SNOT-22 at the&#xD;
             screening visit.&#xD;
&#xD;
          4. History of any surgical procedure that prevents the ability to accurately grade the&#xD;
             nasal polyps&#xD;
&#xD;
          5. Participants who will not be able to complete the follow-up appointments/evaluations&#xD;
&#xD;
          6. Have significant oral structural abnormalities, e.g. unrepaired cleft palate&#xD;
&#xD;
          7. Septal deviation requiring correction in order to perform either EPIC or ESS&#xD;
             procedures&#xD;
&#xD;
          8. Diagnosis of an immunodeficiency or immunocompromised state&#xD;
&#xD;
          9. Diagnosis of cystic fibrosis&#xD;
&#xD;
         10. Diagnosis of allergic fungal sinusitis&#xD;
&#xD;
         11. Contraindication to the use of oral corticosteroids (e.g. uncontrolled diabetes,&#xD;
             congestive heart failure, uncontrolled hypertension, known renal insufficiency, known&#xD;
             peptic ulcer disease, known glaucoma, pregnancy)&#xD;
&#xD;
         12. History of either Churg-Strauss syndrome, primary ciliary dyskinesia, or vasculitis&#xD;
             (e.g. granulomatosis with polyangiitis(GPA))&#xD;
&#xD;
         13. Allergy, hypersensitivity, or contraindication to the use of local or topical&#xD;
             lidocaine anesthetics, nasal topical 1:1000 adrenaline, nasal decongestants, nasal&#xD;
             steroid spray&#xD;
&#xD;
         14. Any serious or unstable concurrent disease, psychiatric disorder, or any significant&#xD;
             condition that, in the opinion of the investigator, could confound the results of the&#xD;
             study or could interfere with the participant's participation or compliance with the&#xD;
             study&#xD;
&#xD;
         15. A recent (within 1 year of the screening visit) clinically significant history of drug&#xD;
             or alcohol abuse, or dependence that, in the opinion of the investigator could&#xD;
             interfere with the participant's participation or compliance with the study&#xD;
&#xD;
         16. Inability to read and understand English&#xD;
&#xD;
         17. Any medical condition that in the opinion of the investigator would interfere with the&#xD;
             treatment&#xD;
&#xD;
         18. Any participant who is unfit to undergo surgery under general anesthesia&#xD;
&#xD;
         19. Current participation in another clinical trial at the time of the screening visit.&#xD;
&#xD;
         20. Participant is unable to undergo an awake procedure&#xD;
&#xD;
         21. Diagnosis or Aspirin Exacerbated Respiratory Disease (AERD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaun Kilty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Lasso, MSc</last_name>
    <phone>6137985555</phone>
    <phone_ext>10222</phone_ext>
    <email>alasso@toh.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Nguyen</last_name>
      <email>kelly.nguyen@alumni.ubc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taciano Rocha</last_name>
    </contact>
    <contact_backup>
      <email>taciano.rocha@sjhc.london.on.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Lasso, MSc</last_name>
      <phone>613-798-5555</phone>
      <phone_ext>10222</phone_ext>
      <email>alasso@toh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Tewfik</last_name>
    </contact>
    <contact_backup>
      <email>marc.tewfik@mcgill.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>September 20, 2022</last_update_submitted>
  <last_update_submitted_qc>September 20, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02975310
org study id: CTO-0801
nct id: NCT02975310
lead sponsor: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Chronic rhinosinusitis, also called chronic sinusitis, is a very common life-long disease
      affecting over 5% of the Canadian population. Its symptoms, including daily facial pain and
      headache, an inability to breath through the nose and complete smell loss, regularly impair
      one's ability to work and to enjoy and participate in daily activities. The annual cost of
      chronic sinusitis to Canada is estimated at $1.3 billion while the government pays an
      estimated $860 million yearly for chronic sinusitis treatment. Chronic sinusitis with polyps,
      the most common type of chronic sinusitis, is usually treated with a combination of
      medications and surgery. Until now, surgical treatment has only been performed in the
      operating room, at a cost of about $3500 per procedure. But, recent studies have shown that a
      new procedure, "in-clinic polyp removal", can provide an improvement in patient symptoms to
      levels equal to those for sinus surgery performed in a hospital operating room. Moreover, in
      clinic polyp removal has additional advantages including a shorter procedure recovery time, a
      significantly lower cost to the health care system (about one-tenth the cost or $450), and a
      shorter wait time for treatment. With the proposed pragmatic trial, the investigators will
      determine whether the in clinic polyp removal procedure is as good as sinus surgery in the
      operating room at controlling patient symptoms of chronic sinusitis. The investigators will
      also determine the cost and health-benefits for a patient, the healthcare system and for
      society of in clinic polyp removal in comparison to sinus surgery done in a hospital
      operating room. The investigators will then know if this new treatment, in clinic polyp
      removal, can replace sinus surgery as the standard of care for these patients.
Chronic rhinosinusitis (CRS) is common, with a Canadian prevalence of 5%, and associated with
      significant morbidity having a health state utility value equivalent to end-stage renal
      disease. Understandably, CRS impairs workplace productivity but that productivity
      substantially increases following surgical treatment.

      However, the wait time to receive surgical treatment (ESS) maybe up to 8 months or longer,
      with a cost to the Government of $3500/ESS procedure. The annual direct cost of CRS is
      estimated at $860 million with an overall financial impact of 1.3 billion dollars per year
      for Canada. Endoscopic polypectomy in clinic (EPIC), a potential disruptive innovation, is a
      drastically deescalated form of ESS performed in clinic instead of the operating room. EPIC
      appears to provide quality of life (QofL) improvement equivalent to that reported for ESS.
      EPIC has a shorter wait time and lower cost to a government, i.e. nearly one-tenth of ESS or
      about $450. A pilot economic evaluation study demonstrated that EPIC was cost-effective
      compared to ESS. This has created a controversy about which treatment should be employed for
      these patients. Further, a recent Cochrane review identified the need for high-quality
      randomised controlled trials to determine if ESS has additional benefit over polypectomy as
      there is currently insufficient evidence to draw conclusions about the superiority of
      polypectomy or ESS for the management of CRS with polyps.

      The proposed national multicenter randomised controlled trial will determine whether EPIC is
      non-inferior to the current treatment standard, ESS, in QofL improvement for patients with
      CRS with polyps. It will also assess the cost-effectiveness of performing EPIC in place of
      ESS. The investigators hypothesize that EPIC will be non-inferior to ESS for QofL improvement
      while reducing health care cost. This would imply that EPIC is a dominant strategy and that
      the ESS strategy represents over-treatment in this patient population. The study findings
      would position EPIC into the current CRS treatment paradigm thereby transforming care and
      reducing costs both nationally and internationally.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Sinonasal Outcome Test-22 (SNOT-22)
time frame: 3 months
measure: Peak Nasal Inspiratory Flow (PNIF):
time frame: 3 months
measure: Iowa Satisfaction with Anesthesia Scale (ISAS)
time frame: 3 months
description: Patient satisfaction with anesthesia for the treatment procedure
measure: Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP)
time frame: 3 months
description: Work Impairment related to chronic rhinosinusitis
measure: EQ-5D-5L
time frame: 3 months
description: Quality of Life
measure: Participant Health Resource Consumption Survey
time frame: 3 months
description: Individual Health Resource Consumption
measure: Adverse Events
time frame: 3 months
measure: Lund-Kennedy Endoscopic Scoring Scale
time frame: 3 months
description: Endoscopic inflammation of the nose and paranasal sinuses after treatment
measure: Visual Analogue Scale (VAS) for satisfaction with assigned procedure
time frame: 3 months
description: Satisfaction with assigned procedure
arm group label: Endoscopic polypectomy in clinic (EPIC)
arm group type: Experimental
description: Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic
arm group label: Endoscopic Sinus Surgery (ESS)
arm group type: Active Comparator
description: Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),
intervention type: Procedure
intervention name: Endoscopic polypectomy in clinic (EPIC)
description: The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
arm group label: Endoscopic polypectomy in clinic (EPIC)
intervention type: Procedure
intervention name: Endoscopic Sinus Surgery (ESS)
description: The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
arm group label: Endoscopic Sinus Surgery (ESS)
intervention type: Other
intervention name: General Anesthesia
description: ESS will be performed under general anesthesia in the operating room
arm group label: Endoscopic Sinus Surgery (ESS)
intervention type: Other
intervention name: Local and topical anesthesia
description: EPIC will be performed under topical and local anesthesia in a clinic setting
arm group label: Endoscopic polypectomy in clinic (EPIC)
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Shaun Kilty, MD
role: Principal Investigator
affiliation: The Ottawa Hospital Research Institute
last name: Andrea Lasso, MSc
phone: 6137985555
phone ext: 10222
email: alasso@toh.ca
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
contact backup: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
contact backup: 
country: Canada
responsible party type: Sponsor
mesh term: Sinusitis
mesh term: Nasal Polyps
mesh term: Polyps
mesh term: Anesthetics
sharing ipd: No